Boehringer brings ear­ly da­ta for GLP-1 re­cep­tor show­ing al­most 15% weight loss af­ter 46 weeks

Boehringer In­gel­heim and Zealand Phar­ma re­leased Phase II da­ta on their weight loss can­di­date, a glucagon and GLP-1 re­cep­tor ag­o­nist called BI 456906, play­ing catch-up with lead­ers like No­vo Nordisk and Eli Lil­ly as the obe­si­ty mar­ket bal­loons.

The da­ta met its pri­ma­ry end­point in the dose-find­ing tri­al: up to 14.9% weight loss af­ter 46 weeks us­ing the planned main­te­nance dose. This study en­rolled pa­tients who are liv­ing with obe­si­ty or are over­weight with­out type 2 di­a­betes.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.